Industry News
Pharmaceutical Industry News
After more than a decade in charge…
After more than a decade in charge of the most influential organization representing the U.S. pharmaceutical industry, PhRMA, Steve Ubl will step down as its CEO at the end of the year.
Japan’s Shionogi is joining the…
Japan’s Shionogi is joining the spate of drugmakers to unveil a U.S. manufacturing commitment, albeit under slightly different circumstances than its peers.
The company is moving out of the…
The company is moving out of the building that used to house the headquarters of its 2022-acquired Global Blood Therapeutics.
Biogen has agreed to a settlement…
Biogen has agreed to a settlement with investors who claimed the company misled them in describing how it gained a controversial FDA approval for failed Alzheimer’s treatment, Aduhelm.
With a solid year of double-digit…
With a solid year of double-digit revenue growth in the books, Amgen’s longtime helmsman Robert Bradway continues to sit firmly in the upper echelons of biopharma CEO pay, though not quite at the level seen
Johnson & Johnson’s…
Johnson & Johnson’s immunology drug Tremfya is looking to challenge AbbVie’s dominance in 2026, securing the top spot as the biggest TV drug ad spender in March.
Cognito Therapeutics is partnering…
Cognito Therapeutics is partnering with a nonprofit to drop the "D-Word," aiming to eliminate the use of “dementia,” a catchall term that can carry stigma.
For the second time in a span of…
For the second time in a span of four months, Insmed’s Brinsupri has come up short in a mid-stage trial designed to expand its use into a new indication.
U.S. Olympic gold medal-winning…
U.S. Olympic gold medal-winning athlete Lindsey Vonn is once again teaming up with infectious disease biopharma Invivyd for a new campaign centering on antibody-based treatments.
Finasteride for Male Baldness is Rewriting the Rules of Male Beauty
A pill to cure baldness is changing the way men age — and how they see themselves.
The plummeting demand for…
The plummeting demand for Merck’s HPV vaccine Gardasil in China has forced the New Jersey drugmaker to rework its arrangement with its partner in the country, Zhifei Biological Products.
Halozyme is putting a recent…
Halozyme is putting a recent drug-delivery acquisition to work thanks to a new tie-up with Vertex Pharmaceuticals.
The FDA is seeking new powers to…
The FDA is seeking new powers to hold companies accountable for misleading direct-to-consumer ads, adding legislative weight to its pushback against deceptive drug advertising.
In response to a warning letter…
In response to a warning letter from the FDA that accused the company of making “false or misleading” claims about its bladder cancer drug Anktiva, ImmunityBio says it’s implementing enhanced protocols.
A recent episode of ABC’s Scrubs…
A recent episode of ABC's Scrubs featured an on-screen brand integration with Insulet's Omnipod device worn by beloved TV doctor Christopher Turk.
Neurocrine Biosciences, forever a…
Neurocrine Biosciences, forever a possible M&A target in the biopharma industry, is making a major acquisition itself. The purchase adds to a recent string of multibillion-dollar deals.
With a new, patient-friendly route…
With a new, patient-friendly route of administration, Amgen may have found a way to increase demand for Tepezza. A phase 3 trial of patients with thyroid eye disease has shown that subcutaneous injection of Tepezza
Eli Lilly has published a video…
Eli Lilly has published a video about how medicines affect lives to mark its 150th anniversary and the arrival of college basketball stars in its home city.
VML Health has published a report…
VML Health has published a report about 10 trends defining the future of healthcare, making the case that pharma marketers must adapt to patients shifting their goals from lifespan to “joyspan.”
In a flurry of activity, biopharma…
In a flurry of activity, biopharma companies pulled off seven transactions in the last two weeks of March worth a combined $29 billion. The blitz indicates that 2026 will be a prime year for M&A